New York Foundling Hospital

The New York Foundling, established in 1869, has dedicated itself to supporting children, adults, and families in their pursuit of stability and independence through a variety of evidence-based programs and services. With a mission grounded in the belief that everyone deserves the opportunity to thrive, the organization partners with local communities to foster transformational change. Offering comprehensive services in child welfare, developmental disabilities, education, health, and juvenile criminal justice, The New York Foundling aims to provide resources that empower individuals to tap into their full potential. By investing in the strengths of its neighbors, the organization works tirelessly to build a brighter future for all. Generated from the website

Michal Bar-Natan, MD, is Associate Professor of Clinical Medicine and a member of the Leukemia Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital in New York City. Dr. Bar-Natan graduated cum laude from the Sackler School of Medicine. She completed her Internal Medicine Residency at Sheba Medical Center and her Fellowship in Hematology and Medical Oncology at NYU Langone Health. In addition to her clinical fellowship training, Dr. Bar-Natan completed a research fellowship at Dana Farber Cancer Institute and Brigham and Women’s Hospital (Harvard Medical School) with a focus on the role that signal transducer and activator of transcription (STAT) proteins play in the development and treatment of myeloproliferative neoplasms (MPNs) and leukemias.Prior to this position Dr. Bar-Natan served as Associate Professor of Medicine at the Icahn School of Medicine at Mt. Sinai, an Attending Physician with the Center of Excellence for Blood Cancers and Myeloid Disorders, and as the leader of the Acute Lymphoblastic Leukemia program at the Mt. Sinai Tisch Cancer Institute. Dr. Bar-Natan’s focus is on translational research in malignant hematology, particularly myeloid malignancies and acute lymphoblastic leukemia, and the development of investigator-initiated clinical trials for patients with these conditions. She leads early phase clinical trials implementing new therapeutic approaches, such as immunotherapies and combination therapies, and serves as the PI and co-investigator on many clinical trials for acute leukemias and myeloproliferative neoplasms.